Equities Analysts Set Expectations for Illumina Q4 Earnings

Illumina, Inc. (NASDAQ:ILMN) – Stock analysts at Leerink Partnrs lowered their Q4 2025 earnings per share estimates for shares of Illumina in a report released on Tuesday, January 7th. Leerink Partnrs analyst P. Souda now anticipates that the life sciences company will earn $1.24 per share for the quarter, down from their previous forecast of $1.25. The consensus estimate for Illumina’s current full-year earnings is $4.11 per share. Leerink Partnrs also issued estimates for Illumina’s FY2026 earnings at $4.90 EPS.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.26. The firm had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The company’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.33 earnings per share.

Other equities analysts have also issued reports about the company. Royal Bank of Canada raised their target price on Illumina from $252.00 to $254.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. Citigroup lowered Illumina from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $190.00 to $165.00 in a report on Wednesday, December 11th. UBS Group boosted their target price on Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Barclays increased their price target on Illumina from $135.00 to $145.00 and gave the company an “equal weight” rating in a report on Tuesday, November 5th. Finally, HSBC raised shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 price objective for the company in a report on Thursday, October 17th. Eight analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $165.95.

Illumina Stock Up 0.4 %

ILMN stock opened at $139.68 on Wednesday. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. Illumina has a 1 year low of $100.08 and a 1 year high of $156.66. The company has a fifty day simple moving average of $141.37 and a 200 day simple moving average of $132.08. The firm has a market cap of $22.15 billion, a PE ratio of -14.02 and a beta of 1.11.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Versant Capital Management Inc increased its holdings in Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after buying an additional 146 shares during the period. TD Private Client Wealth LLC boosted its position in shares of Illumina by 58.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after acquiring an additional 141 shares in the last quarter. Massmutual Trust Co. FSB ADV increased its stake in Illumina by 65.1% in the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock valued at $56,000 after acquiring an additional 168 shares during the period. Itau Unibanco Holding S.A. acquired a new position in Illumina in the second quarter worth about $61,000. Finally, Private Trust Co. NA raised its position in Illumina by 81.2% in the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after purchasing an additional 212 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.